Cargando…

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatien...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicin, Irfan, Oksuz, Ergun, Karadurmus, Nuri, Malhan, Simten, Gumus, Mahmut, Yilmaz, Ulku, Cansever, Levent, Cinarka, Halit, Cetinkaya, Erdogan, Kiyik, Murat, Ozet, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233643/
https://www.ncbi.nlm.nih.gov/pubmed/34173876
http://dx.doi.org/10.1186/s13561-021-00322-2
_version_ 1783713899295539200
author Cicin, Irfan
Oksuz, Ergun
Karadurmus, Nuri
Malhan, Simten
Gumus, Mahmut
Yilmaz, Ulku
Cansever, Levent
Cinarka, Halit
Cetinkaya, Erdogan
Kiyik, Murat
Ozet, Ahmet
author_facet Cicin, Irfan
Oksuz, Ergun
Karadurmus, Nuri
Malhan, Simten
Gumus, Mahmut
Yilmaz, Ulku
Cansever, Levent
Cinarka, Halit
Cetinkaya, Erdogan
Kiyik, Murat
Ozet, Ahmet
author_sort Cicin, Irfan
collection PubMed
description BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. RESULTS: Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. CONCLUSIONS: Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00322-2.
format Online
Article
Text
id pubmed-8233643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-82336432021-06-28 Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective Cicin, Irfan Oksuz, Ergun Karadurmus, Nuri Malhan, Simten Gumus, Mahmut Yilmaz, Ulku Cansever, Levent Cinarka, Halit Cetinkaya, Erdogan Kiyik, Murat Ozet, Ahmet Health Econ Rev Research BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. RESULTS: Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. CONCLUSIONS: Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00322-2. Springer Berlin Heidelberg 2021-06-26 /pmc/articles/PMC8233643/ /pubmed/34173876 http://dx.doi.org/10.1186/s13561-021-00322-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cicin, Irfan
Oksuz, Ergun
Karadurmus, Nuri
Malhan, Simten
Gumus, Mahmut
Yilmaz, Ulku
Cansever, Levent
Cinarka, Halit
Cetinkaya, Erdogan
Kiyik, Murat
Ozet, Ahmet
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title_full Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title_fullStr Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title_full_unstemmed Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title_short Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
title_sort economic burden of lung cancer in turkey: a cost of illness study from payer perspective
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233643/
https://www.ncbi.nlm.nih.gov/pubmed/34173876
http://dx.doi.org/10.1186/s13561-021-00322-2
work_keys_str_mv AT cicinirfan economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT oksuzergun economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT karadurmusnuri economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT malhansimten economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT gumusmahmut economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT yilmazulku economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT canseverlevent economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT cinarkahalit economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT cetinkayaerdogan economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT kiyikmurat economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT ozetahmet economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective
AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective